Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Brain : a journal of neurology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/brain/awq278PMID 20929960
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.

  2009cited by this paper
• Calcium signaling cascade links dopamine D1–D2 receptor heteromer to striatal BDNF production and neuronal growth

  2009cited by this paper
• Gene Dysregulation in Huntington’s Disease: REST, MicroRNAs and Beyond

  2009cited by this paper
• A pilot study using nabilone for symptomatic treatment in Huntington's disease

  2009cited by this paper
• Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease

  2009cited by this paper
• The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.

  2009cited by this paper
• Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models.

  2009cited by this paper
• Emerging strategies for exploiting cannabinoid receptor agonists as medicines

  2009cited by this paper
• Animal welfare and the refinement of neuroscience research methods – a case study of Huntington's disease models

  2008cited by this paper
• Enhanced Sensitivity of Striatal Neurons to Axonal Transport Defects Induced by Mutant Huntingtin

  2008cited by this paper
• Dopaminergic and Glutamatergic Signaling Crosstalk in Huntington's Disease Neurodegeneration: The Role of p25/Cyclin-Dependent Kinase 5

  2008cited by this paper
• Mechanisms of control of neuron survival by the endocannabinoid system.

  2008influential reference
• Huntington's disease: from pathology and genetics to potential therapies.

  2008cited by this paper
• Endocannabinoid signaling as a synaptic circuit breaker in neurological disease

  2008cited by this paper
• The endocannabinoid system in Huntington's disease.

  2008cited by this paper
• Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease.

  2008influential reference
• Huntingtin Regulates RE1-silencing Transcription Factor/Neuron-restrictive Silencer Factor (REST/NRSF) Nuclear Trafficking Indirectly through a Complex with REST/NRSF-interacting LIM Domain Protein (RILP) and Dynactin p150Glued*

  2008cited by this paper
• Huntingtin Modulates Transcription, Occupies Gene Promoters In Vivo, and Binds Directly to DNA in a Polyglutamine-Dependent Manner

  2008cited by this paper
• Analysis of Promoter Regions Regulating Basal and Interleukin-4-Inducible Expression of the Human CB1 Receptor Gene in T Lymphocytes

  2008cited by this paper
• Cannabinoid CB1 and CB2 Receptors and Fatty Acid Amide Hydrolase Are Specific Markers of Plaque Cell Subtypes in Human Multiple Sclerosis

  2007cited by this paper
• Huntington's disease.

  2007cited by this paper
• Cannabinoid CB2 receptor: a new target for controlling neural cell survival?

  2007cited by this paper
• Role of brain-derived neurotrophic factor in Huntington's disease.

  2007influential reference
• Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes.

  2007cited by this paper
• The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases.

  2007cited by this paper
• Transcriptional signatures in Huntington's disease.

  2007cited by this paper
• Mouse and rat BDNF gene structure and expression revisited

  2006cited by this paper
• Nabilone Could Treat Chorea and Irritability in Huntington ’ s Disease

  2006cited by this paper
• The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum.

  2006cited by this paper
• Nabilone could treat chorea and irritability in Huntington's disease.

  2006cited by this paper
• The Endocannabinoid System Promotes Astroglial Differentiation by Acting on Neural Progenitor Cells

  2006cited by this paper
• Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model.

  2005cited by this paper
• Cleavage pattern and emerging asymmetry of the mouse embryo

  2005cited by this paper
• Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation

  2005cited by this paper
• Normal huntingtin function: an alternative approach to Huntington's disease

  2005cited by this paper
• A cell-based screen for drugs to treat Huntington's disease.

  2004cited by this paper
• Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors.

  2004cited by this paper
• Genome-wide analysis of repressor element 1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) target genes.

  2004cited by this paper
• Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice.

  2004cited by this paper
• Involvement of brain‐derived neurotrophic factor in cannabinoid receptor‐dependent protection against excitotoxicity

  2004cited by this paper
• Brain-Derived Neurotrophic Factor Regulates the Onset and Severity of Motor Dysfunction Associated with Enkephalinergic Neuronal Degeneration in Huntington's Disease

  2004cited by this paper
• Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo

  2004cited by this paper
• Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains

  2003cited by this paper
• Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes

  2003cited by this paper
• Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.

  2003cited by this paper
• Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate

  2003cited by this paper
• CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity

  2003influential reference
• Standardization and statistical approaches to therapeutic trials in the R6/2 mouse.

  2003cited by this paper
• The molecular logic of endocannabinoid signalling

  2003cited by this paper
• Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain.

  2002cited by this paper
• Increased Severity of Stroke in CB1 Cannabinoid Receptor Knock-Out Mice

  2002cited by this paper
• Endocannabinoids and Neuroprotection

  2002cited by this paper
• Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease.

  2002cited by this paper
• The endogenous cannabinoid system controls extinction of aversive memories

  2002cited by this paper
• Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease

  2001cited by this paper
• An endogenous cannabinoid (2-AG) is neuroprotective after brain injury

  2001cited by this paper
• Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study.

  2000cited by this paper
• The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.

  2000cited by this paper
• Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice.

  2000cited by this paper
• Localization of cannabinoid CB1 receptor mRNA in neuronal subpopulations of rat striatum: A double‐label in situ hybridization study

  2000cited by this paper
• Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells.

  2000cited by this paper
• Cannabinoids and Neuroprotection in Global and Focal Cerebral Ischemia and in Neuronal Cultures

  1999cited by this paper
• Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain

  1999cited by this paper
• Nabilone increases choreatic movements in Huntington's disease

  1999cited by this paper
• Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases.

  1999cited by this paper
• Differential regulation of the expression of nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 after excitotoxicity in a rat model of Huntington's disease.

  1998cited by this paper
• Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons.

  1997cited by this paper
• Anterograde transport of brain-derived neurotrophic factor and its role in the brain

  1997cited by this paper
• Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.

  1996cited by this paper
• Identification of brain-derived neurotrophic factor promoter regions mediating tissue-specific, axotomy-, and neuronal activity-induced expression in transgenic mice

  1995cited by this paper
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper
• Controlled clinical trial of cannabidiol in Huntington's disease.

  1991cited by this paper
• Huntington's disease

  1984cited by this paper
• Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish

  1964cited by this paper

• Cannabinoids, the Blood-Brain Barrier, and Neurodegeneration: Mechanisms, Dysregulation, and Therapeutic Perspectives.

  2026cites this paper
• Recent Preclinical Evidence on Phytocannabinoids in Neurodegenerative Disorders: A Focus on Parkinson’s and Alzheimer’s Disease

  2025cites this paper
• Restoration of CB1 receptor function in hippocampal GABAergic neurons rescues memory deficits in Huntington’s disease models

  2025cites this paper
• Upregulation of endocannabinoid signaling in vivo restores striatal synaptic plasticity and motor performance in Huntington's disease mice

  2025cites this paper
• Cannabinoid Receptor 2 (CB2R) as potential target for the pharmacological treatment of neurodegenerative diseases.

  2025cites this paper
• Anti-Inflammatory Effects of Cannabinoids in Therapy of Neurodegenerative Disorders and Inflammatory Diseases of the CNS

  2025cites this paper
• Cannabinoid Receptor 1: The Neural Gatekeeper of Health and Disease.

  2025cites this paper
• The Neurotherapeutic Arsenal in Cannabis sativa: Insights into Anti-Neuroinflammatory and Neuroprotective Activity and Potential Entourage Effects

  2024cites this paper
• The Therapeutic Potential and Molecular Mechanisms Underlying the Neuroprotective Effects of Sativex® - A Cannabis-derived Spray.

  2024cites this paper
• Regulation of Cannabinoid and Opioid Receptor Levels by Endogenous and Pharmacological Chaperones

  2024cites this paper
• Phytocannabinoids—Evaluation of their therapeutic role in neuroinflammation

  2024cites this paper
• Effect of chronic upregulation of endocannabinoid signaling in vivo with JZL184 on striatal synaptic plasticity and motor learning in YAC128 Huntington disease mice

  2024cites this paper
• Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications

  2024cites this paper
• Unveiling the Potential of Phytocannabinoids: Exploring Marijuana’s Lesser-Known Constituents for Neurological Disorders

  2024cites this paper
• Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders

  2024cites this paper
• Plants, phytochemicals, and natural practices in complementary and alternative system of medicine for treatment of central nervous system disorders

  2023cites this paper
• THC and CBD: Similarities and differences between siblings.

  2023cites this paper
• Selective inhibition of cannabinoid CB1 receptor-evoked signalling by the interacting protein GAP43.

  2023cites this paper
• An enquiry to the role of CB1 receptors in neurodegeneration.

  2023cites this paper
• BDNF and Cerebellar Ataxia.

  2023cites this paper
• Cannabis Sativa in Phytotherapy: Reappraisal of Therapeutic Potential and Regulatory Aspects.

  2023cites this paper
• Cannabinoid receptor 1 positive allosteric modulator (GAT229) attenuates cisplatin-induced neuropathic pain in mice

  2022cites this paper
• Recent developments in the management of Huntington's disease.

  2022cites this paper
• Potential Neuroprotective Effect of Cannabinoids in Covid-19 Patients.

  2022cites this paper
• Cannabinoids in movement disorders.

  2022cites this paper
• Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells

  2022cites this paper
• Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty

  2022influential citation
• Cannabinoid Receptor 1 Is Required for Neurodevelopment of Striosome-Dendron Bouquets

  2022cites this paper
• Cannabinoid signaling and risk in Huntington's disease

  2022cites this paper
• The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation

  2022cites this paper
• Circulating Endocannabinoids in Huntington’s Disease: An Exploratory Cross-Sectional Study

  2022cites this paper
• The potential roles of excitatory-inhibitory imbalances and the repressor element-1 silencing transcription factor in aging and aging-associated diseases.

  2021cites this paper
• BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis

  2021cites this paper
• The Therapeutic Potential of Cannabis in Counteracting Oxidative Stress and Inflammation

  2021cites this paper
• Endocannabinoid system: Role in blood cell development, neuroimmune interactions and associated disorders.

  2021cites this paper
• ABHD6 Inhibition Rescues a Sex-Dependent Deficit in Motor Coordination in The HdhQ200/200 Mouse Model of Huntington's Disease.

  2021cites this paper
• The Neuroprotective properties, Functions and Roles of Cannabis sativa in selected diseases related to the Nervous System.

  2021cites this paper
• Control of exploration, motor coordination and amphetamine sensitization by cannabinoid CB1 receptors expressed in medium spiny neurons

  2021cites this paper
• Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson’s Disease and Amyotrophic Lateral Sclerosis

  2021cites this paper
• Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC

  2021cites this paper
• Cannabinoid type 1 receptors in A2a neurons contribute to cocaine-environment association

  2021cites this paper
• The endocannabinoid system as a target for the treatment of neurological disorders

  2021cites this paper
• Balancing the Neuroprotective Versus Neurotoxic Effects of Cannabis

  2021cites this paper
• Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson’s and Alzheimer’s Diseases: a Review

  2020cites this paper
• BDNF Activates Postsynaptic TrkB Receptors to Induce Endocannabinoid Release and Inhibit Presynaptic Calcium Influx at a Calyx-Type Synapse

  2020cites this paper
• Cortical and Striatal Circuits in Huntington’s Disease

  2020cites this paper
• An investigation into the targets for cannabinoid action in the ciliate Tetrahymena pyriformis

  2020cites this paper
• Genetic Variation and Sex Mediate Differential Responses to ∆-9-tetrahydrocannabinol among Inbred Mice

  2020cites this paper
• Inhibition of fatty acid amide hydrolase prevents pathology in neurovisceral acid sphingomyelinase deficiency by rescuing defective endocannabinoid signaling

  2020cites this paper
• Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models.

  2020cites this paper
• Inhibition of striatonigral autophagy as a link between cannabinoid intoxication and impairment of motor coordination

  2020cites this paper
• Traditional Herbal Medicines Against CNS Disorders from Bangladesh

  2020cites this paper
• Medical Marijuana Effects in Movement Disorders, Focus on Huntington Disease; A Literature Review.

  2020influential citation
• PET Imaging of the Endocannabinoid System

  2020cites this paper
• G protein-coupled receptors in neurodegenerative diseases

  2020cites this paper
• CB2 Receptor in Microglia: The Guardian of Self-Control

  2020cites this paper
• Alterations in synaptic function and plasticity in Huntington disease

  2019cites this paper
• Bioactive Lipids and the Gut-Brain Axis: Diet as a Modulator of Bioactivity and Diversity of Lipids in the Brain.

  2019cites this paper
• Astroglial monoacylglycerol lipase controls mutant huntingtin‐induced damage of striatal neurons

  2019cites this paper
• Cannabinoids Involvement in Neurodegenerative Diseases

  2019cites this paper
• Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration

  2019cites this paper
• Contribution of Altered Endocannabinoid System to Overactive mTORC1 Signaling in Focal Cortical Dysplasia

  2019cites this paper
• A Single δ9-Tetrahydrocannabinol (THC) Dose During Brain Development Affects Markers of Neurotrophy, Oxidative Stress, and Apoptosis

  2019cites this paper
• Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model

  2019influential citation
• Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders.

  2019cites this paper
• Somatostatin and cannabinoid receptors crosstalk in protection of huntingtin knock-in striatal neuronal cells in response to quinolinic acid.

  2019cites this paper
• Cannabis and Neuropsychiatric Disorders: An Updated Review.

  2019cites this paper
• Heterómeros de receptores CB1, CB2, GPR55 y GPR18: Señalización celular, farmacología y análisis de su potencial como dianas terapéuticas de enfermedades neurodegenerativas

  2018cites this paper
• Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System

  2018cites this paper
• Cannabinoids for Mental and Motor Dysfunctions in Neurodegenerative Diseases

  2018cites this paper
• Dual role of cdk5 on cognitive deficits and striatal vulnerability in huntington's disease

  2018cites this paper
• Medical Use of Cannabinoids

  2018cites this paper
• Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science

  2018cites this paper
• Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

  2018cites this paper
• Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders

  2018cites this paper
• Brain endocannabinoid signaling exhibits remarkable complexity.

  2018cites this paper
• Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington’s disease

  2018cites this paper
• Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington's Disease.

  2018cites this paper
• Neuroprotection by Cannabinoids in Neurodegenerative Diseases

  2018cites this paper
• Sex‐dependent behavioral impairments in the HdhQ350/+ mouse line

  2018cites this paper
• The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases

  2018cites this paper
• Pathway-Specific Control of Striatal Neuron Vulnerability by Corticostriatal Cannabinoid CB1 Receptors

  2018cites this paper
• Synthetic Cannabinoids in Dementia

  2017cites this paper
• Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity

  2017cites this paper
• Cannabis for Basal Ganglia Disorders (Parkinson Disease and Huntington Disease)

  2017cites this paper
• Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation

  2017cites this paper
• Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease

  2017influential citation
• Targeting Phytochemical Driver in AC/cAMP/PKA/CREB Activation: The Next Frontier for Alleviating Huntington’s Type Neurodegenerative Disorders in 3-NP Animal Model: A Complete Review

  2017cites this paper
• Herbal Drugs: A New Hope for Huntington's Disease

  2017cites this paper
• Epilepsy in Other Neurodegenerative Disorders: Huntington’s and Parkinson’s Diseases

  2017cites this paper
• Lipidomics of Stem Cells

  2017cites this paper
• Methylphenidate modifies the motion of the circadian clock Lamotrigine in mood disorders and cocaine dependence Cortical glutamate in postpartum depression Singular Location and Signaling Profile of Adenosine A 2 A-Cannabinoid CB 1 Receptor Heteromers in the Dorsal Striatum

  2017cites this paper
• Singular Location and Signaling Profile of Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Dorsal Striatum

  2017cites this paper
• Endocannabinoid-specific impairment in synaptic plasticity in striatum of 3 Huntington ’ s disease mouse model

  2017cites this paper
• Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3

  2017cites this paper
• Reduced cell size, chromosomal aberration and altered proliferation rates are characteristics and confounding factors in the STHdh cell model of Huntington disease

  2017cites this paper
• Huntington’s Disease Associated Genes: Molecular Basis of Disease and Possible New Targets for Treatment

  2017cites this paper
• Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS

  2017cites this paper
• Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model

  2017cites this paper
• ALLOSTERIC INTERACTIONS WITHIN CANNABINOID RECEPTOR 1 (CB1) AND DOPAMINE RECEPTOR 2 LONG (D2L) HETEROMERS

  2017influential citation